mTOR inhibitors in cancer therapy
| Autor: | Prateek gulhati, Yekaterina Y. Zaytseva, B. Mark Evers, Joseph D. Valentino |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Cancer Research
business.industry TOR Serine-Threonine Kinases Cancer therapy Cancer Antineoplastic Agents P70-S6 Kinase 1 Drug resistance Pharmacology medicine.disease Discovery and development of mTOR inhibitors Clinical trial Oncology Neoplasms Cancer research medicine Humans Molecular Targeted Therapy Signal transduction business PI3K/AKT/mTOR pathway Phosphoinositide-3 Kinase Inhibitors Signal Transduction |
| Zdroj: | Cancer Letters. 319:1-7 |
| ISSN: | 0304-3835 |
| DOI: | 10.1016/j.canlet.2012.01.005 |
| Popis: | The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect